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Surfactant protein-D and pulmonary host defense
Erika C Crouch
Washington University School of Medicine, St Louis, Missouri, USA
Abstract
Surfactant protein-D (SP-D) participates in the innate response to inhaled microorganisms
and organic antigens, and contributes to immune and inflammatory regulation within the
lung. SP-D is synthesized and secreted by alveolar and bronchiolar epithelial cells, but is
also expressed by epithelial cells lining various exocrine ducts and the mucosa of the
gastrointestinal and genitourinary tracts. SP-D, a collagenous calcium-dependent lectin (or
collectin), binds to surface glycoconjugates expressed by a wide variety of microorganisms,
and to oligosaccharides associated with the surface of various complex organic antigens.
SP-D also specifically interacts with glycoconjugates and other molecules expressed on
the surface of macrophages, neutrophils, and lymphocytes. In addition, SP-D binds to
specific surfactant-associated lipids and can influence the organization of lipid mixtures
containing phosphatidylinositol in vitro. Consistent with these diverse in vitro activities is
the observation that SP-D-deficient transgenic mice show abnormal accumulations of
surfactant lipids, and respond abnormally to challenge with respiratory viruses and bacterial
lipopolysaccharides. The phenotype of macrophages isolated from the lungs of SP-D-
deficient mice is altered, and there is circumstantial evidence that abnormal oxidant
metabolism and/or increased metalloproteinase expression contributes to the development
of emphysema. The expression of SP-D is increased in response to many forms of lung
injury, and deficient accumulation of appropriately oligomerized SP-D might contribute to
the pathogenesis of a variety of human lung diseases.
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Introduction
Surfactant protein-D (SP-D) is a member of the collage-
nous subfamily of calcium-dependent lectins (collectins)
that includes pulmonary surfactant protein A (SP-A) and
the serum mannose-binding lectin [1–3]. Collectins inter-
act with a wide variety of microorganisms, lipids, and
organic particulate antigens, and can modulate the func-
tion of immune effector cells and their responses to these
ligands. This article reviews what is currently known about
the sites of production, structure, function, and regulated
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expression of SP-D. Emphasis will be placed on functional
attributes, known ligand interactions, and structure–func-
tion relationships believed to be important for host
defense. For additional information on SP-A and other
members of the collectin family, the reader is referred to
other recent reviews [4–6].
Sites of SP-D production
SP-D is synthesized and secreted into the airspaces of the
lung by the respiratory epithelium [1]. At the alveolar level,
SP-D is constitutively synthesized and secreted by alveo-
lar type II cells. More proximally in the lung, SP-D is
secreted by a subset of bronchiolar epithelial cells, the
non-ciliated Clara cells. Because SP-D is stored within the
secretory granules of Clara cells [7,8], it seems likely that
SP-D is subject to regulated secretion via granule exocy-
tosis at this level of the respiratory tract. In some species,
SP-D is also synthesized by epithelial cells and/or submu-
cosal glands associated with the bronchi and trachea [9].
Although many alveolar macrophages show strong cyto-
plasmic and/or membrane labeling with antibody against
SP-D, they do not contain detectable SP-D message.
The lung seems to be the major site of SP-D production.
However, there is increasing evidence for extrapulmonary
sites of expression as assessed with monoclonal or affin-
ity-purified antibodies, reverse-transcriptase-mediated
PCR (RT–PCR), and/or hybridization assays of tissues
from humans and other large mammals [10•,11–14] (sum-
marized in Table 1). It is difficult to entirely exclude cross-
reactions or amplification of related sequences; however,
localization to many of these sites in human tissues was
Table 1
Known and potential sites of SP-D expression
Anatomical site Organ Cellular source
Respiratory tract/oropharynx/nasopharynx Lung Alveolar type II cell, non-ciliated bronchiolar cells
Trachea and bronchi Submucosal glands and repiratory epithelial cells
Lacrimal glands Ductal epithelial cells
Salivary gland Ductal epithelial cells
Eustachian tube Squamous epithelium
Gastrointestinal tract Esophagus Squamous epithelium
Stomach Glandular epithelial cells
Small intestine Mucosal epithelial cells
Pancreas (exocrine) Ductal epithelial cells (and islets)
Biliary tract Intrahepatic ductal epithelial cells
Genitourinary tract Prostate Glandular epithelium
Bladder Transitional epithelium
Kidney Collecting duct epithelium
Uterus Endometrium/endocervical epithelium?
Fetal membranes ?
Skin and soft tissue Cutaneous squamous epithelium Squamous epithelium
Sweat glands Ductal epithelium
Sebaceous glands Glandular epithelium
Breast Mammary epithelium
Mesentery ?
Other Heart ?
Brain ?
Testis Leydig cells
Pancreas (endocrine) Islets
Placenta ?
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confirmed by using monoclonal antibodies in combination
with RT–PCR with sequencing of the amplified products
[10•]. Non-pulmonary expression seems to be largely
restricted to cells lining epithelial surfaces or ducts and
certain glandular epithelial cells that are in direct or indi-
rect continuity with the environment. Notable exceptions
to this generalization might include heart, brain, pancreatic
islets, and testicular Leydig cells. SP-D has also been
identified in amnionic epithelial cells by immunohistochem-
istry [15]; however, it is unclear whether this is synthe-
sized locally or derived from the lung by way of the
amniotic fluid. Interestingly, in many of these sites SP-D
microscopically co-localizes with gp-340, an SP-D binding
protein and putative SP-D receptor [10•].
Sites of extrapulmonary expression have also been
described in small mammals. In the rat, SP-D message
was identified in RNA extracted from skin and blood
vessel [16], and both protein and message were identified
in gastric mucosa [17] and mesentery [13]. Using
RT–PCR, SP-D message has also been identified in
mouse stomach, heart, and kidney [14].
SP-D structure
SP-D (43 kDa, reduced) consists of at least four discrete
structural domains: a short, N-terminal domain; a relatively
long collagenous domain, a short amphipathic connecting
peptide or coiled-coil neck domain, and a C-terminal, C-
type lectin carbohydrate recognition domain (CRD). Each
molecule consists of trimeric subunits (3 × 43 kDa), which
associate at their N-termini (Fig. 1). Although most prepa-
rations of SP-D contain a predominance of dodecamers
(that is, four trimeric subunits), the proportions of various
oligomers vary between species. For example, rat lavage
and recombinant rat SP-D are almost exclusively assem-
bled as dodecamers (four trimers), whereas recombinant
human SP-D is secreted as trimers, dodecamers and
higher-order multimers [18]. SP-D isolated from the lavage
of some patients with alveolar proteinosis consists pre-
dominantly of higher-order multimers, which can contain
up to 32 (or more) trimeric subunits (Fig. 1).
Neck and CRDs
Recent crystallographic and mutagenesis studies suggest
that the structural determinants of saccharide binding are
similar to those originally described for mannose-binding
lectin [19,20,21•,22•]. At least two bound calcium ions
and two intrachain disulfide crosslinks stabilize the
required tertiary structure, and Glu321 and Asn323 within
the CRD participate in glucose/mannose type recognition.
Interactions with at least one glycolipid ligand, phos-
phatidylinositol (PI), require the participation of the C-ter-
minal end of the protein [23,24].
A trimeric cluster of CRDs is necessary for high-affinity
binding to carbohydrate ligands [21•,25]. The crystal
structure of human SP-D suggests that the spatial distrib-
ution of CRDs within a trimeric subunit permits simultane-
ous and cooperative interactions with two or three
glycoconjugates displayed on the surface of a particulate
ligand [21•]. Furthermore, solid-phase binding studies
have shown that monomeric CRDs have an approximately
10-fold lower binding affinity for multivalent ligands than
trimeric CRDs.
Crystallographic studies of human SP-D further suggest
that the spatial organization of CRDs within a trimer is sta-
bilized by interactions of the C-terminal sequence with the
trimeric neck domain [21•,26]. Interestingly, the three
CRDs show a deviation from threefold asymmetry, sug-
gesting some flexibility of the CRDs in relation to the neck.
Thus, the dependence of the binding of PI on the C-termi-
nal sequence could reflect conformational effects, rather
than the direct participation of this sequence in ligand
interactions.
Collagen domain
The collagen domain length of SP-D is highly conserved
and lacks interruptions in the repeating Gly-X-Y sequence
Figure 1
Molecular structure of SP-D. (a) Schematic diagram illustrating the
structure of SP-D dodecamers, which consist of four trimeric subunits,
and SP-D trimers. (b) Quick-freeze deep-etch image of human SP-D
dodecamers, SP-D multimers, and the SP-D binding protein gp-340
(kindly provided by John Heuser, Washington University School of
Medicine, St Louis, Missouri, USA).
(in which X and Y are different amino acids). As for other
collagenous proteins, this domain is enriched in imino
acids and contains hydroxyproline. Unlike SP-A, SP-D also
contains hydroxylysine. Although the collagen domain of
rat, human, bovine, and mouse SP-D lacks cysteine
residues, cDNA sequencing has identified a codon for
cysteine within the collagen domain of pig SP-D [27•]; this
suggests the possibility of alternative patterns of chain
association and oligomeric assembly for pig SP-D.
The first translated exon of SP-D contains a highly con-
served and unusually hydrophilic Gly-X-Y sequence that
shows little homology with the remainder of the collagen
sequence. The functional significance of this region is
unknown. However, it has been suggested that this region
contributes to oligomer assembly or mediates interactions
with cellular receptors.
The collagen domain determines the maximal spatial sep-
aration of trimeric, C-terminal lectin domains within SP-D
molecules, but might also contribute to normal
oligomeric assembly and secretion. For example, dele-
tion of the entire collagen domain of rat SP-D results in
the secretion of trimers rather than dodecamers [28]. In
addition, 2,2-dipyridyl, an inhibitor of prolyl hydroxylation
that interferes with the formation of a stable collagen
helix, causes the intracellular accumulation of 43 kDa
monomers and dimers [29]. In any case, the complete
conservation of the number of Gly-X-Y triplets suggests
that the spatial separation of trimeric CRDs is critical for
normal SP-D function.
N-terminal domain
The N-terminal peptide of the mature protein contains two
conserved cysteine residues at positions 15 and 20.
These residues participate in interchain disulfide
crosslinks that stabilize the trimer, as well as the N-termi-
nal association of four or more trimeric subunits. Stable
oligomerization of trimeric subunits permits cooperative or
bridging interactions between spatially separated binding
sites on the same surface or on different particles.
The process of forming interchain disulfide bonds is
complex, and appropriate crosslinking of the N-terminal
domains might be rate limiting for secretion [30]. Subcel-
lular fractionation studies suggest that interchain bonds
form initially between the three chains of a trimeric subunit.
Subsequent rearrangements within the rough endoplas-
mic reticulum might allow the covalent crosslinking of a
single chain from one subunit and two crosslinked chains
of another, with the associated elimination of free thiol
groups. Mutant proteins that contain unpaired N-terminal
cysteine residues are not secreted. However, it is unclear
whether this results from abnormalities in disulfide
bonding itself, or the failure to stabilize the required N-ter-
minal conformation.
Glycosylation of SP-D
The collagen domain contains hydroxylysyl-derived glyco-
sides and a single N-linked oligosaccharide. In most
species (human, rat, mouse, and cow) the site of N-linked
glycosylation is located near the N-terminal end of the col-
lagenous domain. Recently, it was shown that pig SP-D has
an additional potential site of N-linked glycosylation within
the CRD [27•]. Although rat and human lung lavage SP-D
seem to be sialylated, as suggested by charge heterogene-
ity and cleavage with highly purified neuraminidase, prepara-
tions of human amniotic fluid and bovine lavage SP-D
recovered from amniotic fluid showed predominantly
complex type biantennary structures and no sialic acid [31].
A variant form of SP-D (50 kDa) has been identified in
lavage from a subset of human lavage samples; this
protein shows O-linked glycosylation of threonyl residues
within the N-terminal peptide domain [32•]. At present, the
functional significance of these sugars is not known. The
presence of O-linked glycosylation within the N-terminal
domain might be predicted to interfere with normal dode-
camer assembly. In this regard, the O-glycosylated 50 kDa
form of human SP-D is recovered as trimeric subunits or
smaller species.
As for many glycoproteins, the functional role of the
attached carbohydrate is unknown. Mutational analysis
has shown that the N-linked sugar on rat SP-D is not
required for secretion, for dodecamer formation, or for
interactions with a variety of microorganisms [29,33].
SP-D ligands
Consistent with its designation as a ‘mannose-type’ C-type
lectin, SP-D preferentially binds to simple and complex sac-
charides containing mannose, glucose, or inositol [34,35].
SP-D also interacts with specific constituents of pulmonary
surfactant including PI [36–38] and glucosylceramide [39].
Binding to glucosylceramide involves interactions of the
carbohydrate-binding sequences of the CRD with the glu-
cosyl moiety. However, the interaction of SP-D with PI
involves interactions with the lipid, as well as CRD-depen-
dent interactions with the inositol moiety [24,40].
Microorganisms are surfaced with a diverse and complex
array of polysaccharides and glycoconjugates, and most
classes of microorganism contain one or more sugars rec-
ognized by SP-D. However, the outcome of this interac-
tion depends on the specific organism and can be
modified by the conditions of microbial growth. The poten-
tial consequences of this interaction include the following:
varying degrees of lectin-dependent aggregation (namely,
microbial agglutination), enhanced binding of microorgan-
isms or microbial aggregates to their ‘receptors’ on host
cells, phagocyte activation, and opsonic enhancement of
phagocytosis and killing, potentially involving one or more
cellular receptors for SP-D.
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Interactions of SP-D with microorganisms
Gram-negative bacteria
SP-D binds to many — if not most — species of Gram-neg-
ative bacteria including such important pulmonary
pathogens as Pseudomonas aeruginosa, Klebsiella pneu-
moniae, and Haemophilus influenzae [41] (Table 2).
However, SP-D also binds to certain Gram-positive organ-
isms including strains of Streptococcus pneumoniae and
Staphylococcus aureus [42], and to mycobacteria [43••].
Binding to organisms in suspension is often — but not
always — accompanied by some degree of aggregation.
Mechanisms of interaction
SP-D binds to purified lipopolysaccharide (LPS) isolated
from a variety of Gram-negative organisms [35,41]. In
addition, LPS is the major cell wall component that is
labeled on lectin blotting of outer membranes isolated
from Escherichia coli [41]. The latter interactions involve
the recognition of the core oligosaccharide domain, which
contains glucose and heptose [41]. SP-D interacts prefer-
entially with purified LPS molecules characterized by short
or absent O-antigens and preferentially agglutinates bac-
terial strains expressing a predominance of rough
(O-antigen-deficient) LPS [41,44].
Although the core oligosaccharide domain of LPS con-
stitutes the major ligand for SP-D on at least some
Gram-negative bacteria, the mechanism of interaction
with this group of microorganisms is probably heteroge-
neous. SP-D binds to some smooth, unencapsulated
strains of Gram-negative bacteria by immunofluores-
cence. The mechanism is uncertain; the quantity or
quality of binding differs from that observed for rough
strains and does not necessarily result in agglutination.
LPS molecules on the surfaces of bacteria show hetero-
geneity in the extent of maturation, so it is possible that
this interaction is mediated by a subpopulation of LPS
with deficient O-antigens and that the density of binding
sites is too low for high-affinity binding.
Determinants of binding to cell wall LPS
The recognition of the surface glycoconjugates on Gram-
negative bacteria by SP-D depends not only on the
expression of lectin-specific residues by a given strain or
species, but also on the accessibility of these residues
[1,45]. For example, SP-D binds inefficiently to the core
region of LPS of encapsulated Klebsiella, but efficiently
agglutinates the corresponding unencapsulated phase
variants. Interactions of SP-D with the core oligosaccha-
rides of Gram-negative organisms are also influenced by
the number of repeating saccharide units associated with
the terminal O-antigen of the LPS [41,44].
Other Gram-negative ligands
Other potential ligands include the O-antigen domain of
LPS, certain capsular polysaccharides, and membrane-
associated glycoproteins. In this regard, SP-D can bind to
di-mannose containing O-antigens expressed by a subset
of Klebsiella serotypes (I Ofek, H Sahly and EC Crouch,
unpublished data). Although other C-type lectins, specifi-
cally SP-A and the mannose receptor, can interact with
specific capsular polysaccharides [46], a specific interac-
tion of SP-D with capsular glycoconjugates or exopolysac-
charides has not been described.
Other bacterial organisms
Gram-positive bacteria
The mechanism of interaction with Gram-positive organ-
isms has not been elucidated. Lipoteichoic acids, which
are the major glycolipids associated with the Gram-posi-
tive cell wall, do not detectably compete with LPS for
binding to SP-D (I Ofek, A Mesika, M Kalina, Y Keisari, D
Chang, D McGregor and EC Crouch, manuscript submit-
ted). In preliminary studies we observed that binding was
competed only partly with maltose and/or EDTA, raising
the possibility that binding might be more complex than for
some Gram-negative organisms.
http://respiratory-research.com/content/1/2/093
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Table 2
Interactions of SP-D with bacterial glycoconjugates
Group Organism Glycoconjugates(s) References
Gram-negative bacteria Klebsiella pneumoniae LPS core (cap-) [45,111]
Pseudomonas aeruginosa LPS? [47•]
Escherichia coli LPS core [41,48]
Gram-positive bacteria Staphylococcus aureus Not defined [42]
Streptococcus pneumoniae Not defined [42]
Other Mycobacterium tuberculosis Lipoarabinomannan [43••]
Mycobacteria
Recently, SP-D was shown to interact with the terminal
mannosyl-oligosaccharides of lipoarabinomannan from
Mycobacterium tuberculosis [43••].
Cellular consequences of SP-D binding to bacteria
The consequences of binding with regard to host cell func-
tion are not always predictable. Opsonization of mucoid
strains of P. aeruginosa with rat SP-D enhanced the inter-
nalization by alveolar macrophages, and these experiments
further suggested the involvement of a cellular receptor for
SP-D [47•]. Interestingly, the organisms were not
detectably aggregated by SP-D. Similarly, human SP-D
enhanced the internalization and killing of unencapsulated
phase variants of Klebsiella pneumoniae [45] (I Ofek, A
Mesika, M Kalina, Y Keisari, D Chang, D McGregor and EC
Crouch, manuscript submitted). However, unlike the situa-
tion reported for P. aeruginosa, the organisms showed
varying degrees of aggregation; some of the largest aggre-
gates were identified in association with the macrophage
membrane, but were not internalized. In other studies,
human proteinosis SP-D did not enhance the internalization
of E. coli J5, a rough laboratory strain, by rat alveolar
macrophages, despite efficient bacterial agglutination [48].
In addition, SP-D inhibited the adherence of Mycobac-
terium tuberculosis to monocyte-derived macrophages,
despite efficient microbial aggregation [43••].
Rat and human SP-D enhanced the binding and uptake of
E. coli K12, Streptococcus pneumoniae, and Staphylococ-
cus aureus by human neutrophils [42]. However, similar
effects were observed when the neutrophils were preincu-
bated with SP-D, and there was only a slight enhancement
of uptake when bacteria were incubated with human SP-D
and washed before their addition to neutrophils. Notably,
the extent of binding and internalization was dependent on
the extent of multimerization, with human SP-D multimers
demonstrating the highest potency. Differences in cell type,
the extent of SP-D multimerization, or differences in size or
organization of bacterial aggregates could account for
some of the apparent inconsistencies.
Interactions with bacterial endotoxin
Although LPS mediates the binding of SP-D to at least
some Gram-negative bacteria, SP-D can also bind to spe-
cific forms of soluble LPS, particularly ‘rough’ or O-
antigen-deficient forms [35,41,44]. Because soluble LPS
can modulate a variety of cellular responses and is the key
mediator of Gram-negative sepsis, such interactions could
have considerable biological significance. Several obser-
vations suggest a potential protective role of SP-D in the
host response to endotoxin. For example, SP-D can bind
to intratracheally instilled LPS in rats, and the resulting
complexes are rapidly internalized into lysosomal compart-
ments in alveolar macrophages [49•]. In addition, as dis-
cussed below, preliminary studies suggest that transgenic
mice deficient in SP-D develop more intense inflammation
in response to intratracheal challenge with LPS [50]. Of
particular interest is the recent observation that SP-D can
bind directly to oligosaccharides on sCD14, a soluble
form of one component of the LPS receptor complex, and
modify its interactions with LPS [51•].
Although SP-A can bind to LPS, the interaction is mecha-
nistically different and involves interactions with the lipid A
domain, and perhaps saccharides associated with certain
O-antigens. Human SP-A, but not SP-D, increases the
uptake and deacylation of tritiated E. coli LPS by isolated
alveolar macrophages [52], but the biological significance
of this finding is uncertain.
Pneumocystis and fungi
Pneumocystis
SP-D binds in a CRD-dependent manner to gpA (gp-140),
a heavily mannosylated glycoprotein associated with the
trophozoites and cysts of Pneumocystis carinii [53]. SP-D
can also bind to cell wall β-glucans [54]. SP-D binding
enhances the association of Pneumocystis carinii with rat
alveolar macrophages; however, the bound organisms are
not efficiently internalized or killed in vitro [53].
True fungi
SP-D interacts with most of the clinically important fungal
pathogens including Cryptococcus neoformans, Aspergillus
fumigatus, and Candida albicans [55–57]. We have also
observed binding to clinical isolates of Histoplasma cap-
sulatum and Blastomyces dermatitidis (SF Kuan, S Moser
and E Crouch, unpublished data). In all cases reported so
far, binding is accompanied by agglutination. In particular,
SP-D efficiently agglutinates Aspergillus fumigatus
conidia [55] and Candida albicans [57]. Although SP-D
also shows CRD-dependent agglutination of unencapsu-
lated forms of Cryptococcus neoformans, no significant
binding to encapsulated organisms was observed [56].
There is still relatively little information on the mechanism
of SP-D binding to fungi. However, SP-D shows CRD-
dependent binding to the N-linked sugars of specific cell
wall glycoproteins, including major glycoprotein allergens,
of Aspergillus fumigatus [55]. Because SP-D shows
lectin-dependent binding to wild-type Saccharomyces
cerevisiae, as well as to mutants with low levels of manno-
sylphosphate in the cell wall, the interactions probably do
not involve N-linked phosphomannan sugars [58]. The
observation that SP-D interacts with β-glucans on the
surface of Pneumocystis [54] suggests that these glyco-
conjugates, which are abundant in the cell walls of true
fungi, could serve as ligands for SP-D.
As for bacteria, the effects of SP-D binding on the phago-
cytic response to fungi are somewhat controversial.
Human SP-D enhances the oxidative response to, and
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internalization and killing of, Aspergillus fumigatus conidia
by human alveolar macrophages and blood neutrophils
[59•]. However, other investigators observed binding of rat
and human SP-D to conidia but found no enhancement of
internalization by rat alveolar macrophages [60]. Further-
more, rat SP-D inhibits the phagocytosis of Candida albi-
cans by these cells [57].
In the latter study the authors suggested that fungal
aggregation inhibits phagocytosis. Interestingly, SP-D
binding directly inhibited fungal growth and decreased the
outgrowth of pseudohyphae, the invasive form of the
fungus, in the absence of phagocytic cells [57]. It is possi-
ble that these effects are also secondary to agglutination,
possibly as result of nutrient deprivation.
Respiratory viruses
Purified rat and human SP-D inhibit the infectivity and
hemagglutination activity of influenza A virus (IAV) in vitro
[61•]. This activity is calcium-dependent, inhibited by car-
bohydrate ligands, and involves the binding of SP-D to
high-mannose oligosaccharides associated with the HA1
domain of the hemagglutinin (HA) molecule. Because the
high-mannose oligosaccharide on the HA1 domain over-
lies the sialic acid-binding pocket (the cell attachment site)
of the HA, binding can interfere sterically with HA activity
and cellular attachment. SP-D also binds to the neu-
raminidase of IAV and inhibits neuraminidase enzyme
activity [62].
SP-D induces massive aggregation of IAV particles
[18,33,61•,63]. Viral aggregation is calcium-dependent,
inhibited by competing sugars, and directly correlated with
the multimerization state of SP-D. Highly multimerized
preparations of SP-D are significantly more potent than
dodecamers. In particular, minimal agglutination is induced
with trimeric CRDs. Massive agglutination of organisms
could contribute to lung host defense by promoting airway
mucociliary clearance, but it might also influence the inter-
nalization by phagocytic cells.
SP-D enhances the binding and uptake of IAV by neu-
trophils [33,61•,63], and these effects are highly depen-
dent on the extent of multimerization of SP-D and its ability
to agglutinate the viral particles [18,30,33]. The enhance-
ment of viral binding and uptake is accompanied by
attachment of large aggregates of virus to the neutrophil,
and the binding of IAV or SP-D–IAV aggregates is abro-
gated by pretreatment of the phagocyte with neu-
raminidase [63]. Thus, viral internalization involves
enhanced binding of the virus to sialylated glycoconjugate
ligands on the neutrophil surface. SP-D also potentiates
IAV-induced hydrogen peroxide responses in neutrophils,
and protects neutrophils from IAV-induced inhibition of
respiratory burst responses. Interestingly, SP-D does not
increase the uptake of IAV by rat alveolar macrophages
[64]. Thus, there might be cell type specific effects of SP-
D on phagocytic cells. Notably, human bronchoalveolar
lavage (BAL) contains sufficient concentrations of SP-D to
inhibit IAV HA activity in vitro, and depletion of SP-D from
BAL reduces its HA inhibitory activity [61•].
SP-D can also interact with other respiratory viruses. For
example, natural SP-D and a recombinant trimeric SP-D
bind to the Rous sarcoma virus G protein in vitro and
inhibit viral infectivity in vivo [65•]. These studies suggest
that CRD-dependent binding, but not aggregation, is
required to mediate the antiviral effect. In addition, bovine
SP-D inhibits the infectivity of rotaviruses through calcium-
dependent, mannose-inhibitable, attachment to the major
viral envelope glycoprotein [66].
Interactions of SP-D with host cells
SP-D can interact with host cells, both directly and indi-
rectly. As indicated above, SP-D can enhance the phago-
cytosis and killing of certain microorganisms and enhance
the oxidant response to microbial binding. However, at
present there is only one study that suggests that the
enhancement of phagocytosis by SP-D might involve the
participation of an opsonic receptor. Furthermore, the
enhanced uptake of IAV seems to be mediated by viral
aggregation, with enhanced interactions of the virus with
its natural receptors on the host cell.
In any case, SP-D can interact directly with host cells, and
in some cases can influence their behavior. SP-D is
chemotactic and haptotactic for neutrophils and certain
mononuclear phagocytes [59•,67–69] and can elicit direc-
tional actin polymerization in alveolar macrophages [69]. In
this regard, SP-D is considerably more potent than SP-A.
Early studies with natural proteins isolated from silicotic
animals reported directed effects on the oxidant metabo-
lism of isolated alveolar macrophages [70]. However, such
effects can probably be attributed to endotoxin contamina-
tion and/or aggregation. Purified dodecamers do not sig-
nificantly increase the production of nitric oxide [71] or of
proinflammatory cytokines such as tumor necrosis factor-α
(Y Kesari, H Wang, A Mesika, E Crouch and I Ofek,
unpublished data). Interestingly, purified SP-D has been
reported to increase the production of several metallopro-
teinases in the absence of a significant effect on proin-
flammatory cytokine production [72].
SP-D receptors
Despite the ability of SP-D to modulate a variety of cellular
functions, little is currently known about potential cellular
receptors for this protein. The uptake of mucoid strains of P.
aeruginosa is decreased when macrophages are attached
to slides coated with SP-D, in comparison with lysine-
coated slides, suggesting the redistribution of a membrane
receptor [47•]. In addition, SP-D is internalized by phago-
cytic cells and can be identified within phagolysosomal
http://respiratory-research.com/content/1/2/093
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compartments [73], but it is unclear whether the uptake is
receptor dependent and whether SP-D is being internalized
in association with specific ligands.
There are at least two classes of binding to host cells:
CRD-dependent and CRD-independent. Some studies
have demonstrated CRD-dependent binding to phago-
cytes that can be inhibited with EDTA or competing sac-
charides, both in vitro and in vivo.
CRD-dependent cell binding
As indicated above, the ability of SP-D to elicit the chemo-
taxis of neutrophilic and monocytic cells depends on the
lectin activity of SP-D [68]. In addition, Kuan and co-
workers reported that extracting formaldehyde-fixed alveo-
lar macrophages with detergents largely eliminates the
binding of purified SP-D, suggesting a membrane-associ-
ated ligand or glycolipid receptor [73]. Dong and Wright
have extended these findings and suggest that PI can
contribute to SP-D binding by alveolar macrophages [74].
It is of interest that SP-D can bind to recombinant sCD14
through interactions with N-linked oligosaccharides [51•].
Given that the membrane-associated form of CD14 is widely
expressed on host cells, it is possible that CD14 can serve
as a binding site on macrophages and other cell types.
The phagocytic uptake of certain bacteria by neutrophils is
also inhibited by calcium chelation or competing sugars
[42]; however, this could result from the inhibition of micro-
bial agglutination rather than lectin-dependent interactions
with the phagocyte. Wang et al suggested that SP-D can
bind to lymphocytic cells by a lectin-dependent mechanism
[75••]. In this regard, it is interesting to note that glucosyl-
ceramide, a ligand for SP-D in vitro, is one of the most
abundant neutral glycolipids expressed by lymphoid cells.
CRD-independent cell binding
Reid and co-workers were the first to present evidence for
lectin-independent binding [76]. These and other studies
suggested that binding does not involve known C1q or col-
lectin receptors. The only putative receptor protein, gp-
340, is a widely expressed member of the scavenger
receptor superfamily [77,78•]. It binds to the CRD of SP-D
in a calcium-dependent manner that does not require the
lectin activity of SP-D. Although the protein has been
immunolocalized to alveolar macrophage membranes and
distributes together with SP-D in many different human
tissues [10•,77], it has not yet been shown to mediate the
binding of SP-D to these cells or to participate in signal
transduction events. The cDNAs isolated from lung have
not shown a membrane-spanning region [77], and the
protein is abundant as a soluble component in BAL. Given
that gp-340 is a highly multimerized protein that contains
numerous potential ligand binding domains (Fig. 1b), it is
possible that the protein cooperates with SP-D in the neu-
tralization or clearance of certain ligands rather than specif-
ically mediating the interactions of SP-D with host cells.
Interactions with type II cells
Wright and co-workers have demonstrated the binding
of SP-D to isolated type II pneumocytes. The mechanism
seems distinct from the binding to macrophages [79•].
The binding was dependent on concentration, time, and
temperature and required calcium; it was not sensitive to
protease treatment or to PI-phospholipase C. Although
the internalized SP-D was degraded or recycled to
lamellar bodies, SP-D binding did not alter the uptake of
surfactant lipids.
‘Charging’ of SP-D versus SP-D-dependent
ligand aggregation: hypotheses
SP-D has demonstrated comparatively few direct effects
on the metabolism of host cells, at least in situations where
self-aggregation and endotoxin contamination have been
excluded. One possible explanation is that modulation of
cellular function requires the prior interaction of SP-D with
a ligand. This would have numerous potential physiological
advantages, because the presence of ‘active’ protein might
be restricted to sites of microbial or antigenic deposition.
The binding of complex, multivalent, particulate antigens to
two or more CRDs could markedly alter the conformation
of SP-D molecules, with respect to the spatial orientation
of the arms in relation to the N-terminal crosslinking domain
and/or with respect to the spatial orientation of the CRDs
within a given trimeric subunit. Thus, the ‘charging’ of SP-D
with a particulate ligand could lead to local or distant con-
formational changes that expose ‘cryptic’ binding sites for
cellular receptors.
There is some preliminary evidence consistent with the
notion that the interaction of SP-D with a ligand alters its
capacity to activate host cells. For example, Ofek et al have
examined the effects of SP-D, LPS, and LPS-coated latex
beads on the production of nitric oxide by alveolar
macrophage-like cells (I Ofek, A Mesika, M Kalina, Y Keisari,
D Chang, D McGregor and EC Crouch, manuscript submit-
ted). Under conditions in which SP-D, LPS, latex beads, or
latex beads coated with SP-D or LPS were no more than
minimally stimulatory, the opsonization of LPS-coated latex
beads with SP-D resulted in a marked increase in NO pro-
duction (I Ofek, A Mesika, M Kalina, Y Keisari, D Chang, D
McGregor and EC Crouch, manuscript submitted).
Although these effects can be abrogated with competing
sugars, it is unclear whether the inhibitory effect of compet-
ing sugars involves the disruption of the interaction of SP-D
with the ligand, the host cell, or both. All the effects could
be secondary to altered presentation of the aggregated par-
ticles to receptors for the particulate ligand on the host cell.
Thus, it is unclear whether one needs to invoke the partici-
pation of an SP-D receptor for many of its functions. It is
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well established that the binding of SP-D to IAV particles
leads to aggregation-dependent enhancement of viral
binding to neutrophils, with an increased oxidative
response [45]. These effects involve the natural receptors
for the virus on the neutrophil. Significantly, the effects on
neutrophil function are blocked by enzymic destruction of
the sialic acid-binding sites for the HA on the neutrophil
membrane [63], suggesting that the effects of SP-D do
not require cellular recognition of the bound protein.
Aggregation might also be important for mediating the
interactions of neutrophils with some bacteria [42].
Lipid aggregation and surfactant homeostasis
Particle aggregation might be particularly important for
other aspects of SP-D function. The relatively large spatial
separation of CRDs seems highly suited to bridging inter-
actions between particles with resultant aggregation, as
demonstrated by experiments with IAV. Particle aggrega-
tion could similarly contribute to the metabolism of certain
subfractions of surfactant lipid. For example, Poulain et al
have shown that SP-D can mediate the formation of char-
acteristic tubular configurations of lipid mixtures contain-
ing PI [80•]. Similar structures have been identified in
association with type II cells in culture, and in alveolar pro-
teinosis lavage. In addition, Persson et al demonstrated
the aggregation of PI-containing liposomes [36].
Modulation of SP-D function
A variety of factors can modulate the lectin activity of SP-D
in vitro and might influence SP-D activity in vivo. Selected
examples are listed in Table 3 and discussed below.
Altered patterns of oligomerization
SP-D can be isolated in different multimeric forms from
proteinosis lavage [32•] and are produced by Chinese
hamster ovary K1 cells transfected with human SP-D
cDNA [18]. As described previously, the effects of SP-D
on the neutrophil response to influenza virus are highly
dependent on the ability of SP-D to agglutinate the viral
particles, and the agglutination activity is directly corre-
lated with the extent of multimerization. Trimers can bind
to the virus but have little capacity to modulate neutrophil
interactions. By contrast, highly multimerized proteins
show greater activity than dodecamers [81].
Given these observations, factors that favor enhanced
oligomerization or lead to the accumulation of trimeric sub-
units promote might influence SP-D function. For example,
the liberation of active trimers by a hypothetical microbial
protease could lead to the accumulation of molecules that
might inhibit the aggregation-dependent activities of SP-D.
In contrast, recombinant trimeric CRDs can stimulate
chemotaxis [67] and decrease viral infectivity [65•].
Although higher-order oligomers of SP-D can self-aggre-
gate and precipitate in the presence of calcium in vitro,
the functional consequences are not known.
Biochemical modifications to the CRD
The lectin activity of SP-A is decreased after the nitric
oxide-dependent nitration of tyrosine residues [82], and
nitration decreases the ability of SP-A to enhance the
adherence of Pneumocystis to alveolar macrophages
[83]. However, similar findings have not yet been reported
for SP-D. Conditions of mildly acidic pH, as might be
found in endocytic compartments, are predicted to disrupt
the lectin-dependent activities of SP-D [34]. Proteolytic
degradation remains an important possibility. However,
SP-D is highly resistant to degradation by a wide variety of
neutral proteases in vitro, and degradation products have
not yet been shown to accumulate under pathological
conditions in vivo.
Competing ligands
Glucose concentrations at levels encountered in diabetes
can interfere with SP-D’s ability to interact with specific
strains of IAV or other microorganisms in vitro [84•]. Many
microorganisms release cell wall polysaccharides or gly-
coconjugates, which might interfere with the binding of
collectins to the same or other organisms. In this regard,
SP-D recovered from rats after the instillation of LPS into
the airway shows decreased lectin activity, which is attrib-
uted to occupancy of the CRD with LPS [49•]. It seems
reasonable to speculate that some organisms might
compete with other organisms for binding to SP-D. Such
a situation could conceivably predispose to secondary
infections. Lastly, the potential inhibitory effects of
competing saccharide ligands presents important method-
ological considerations for experiments using carbo-
hydrate-containing cell culture medium or buffers.
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Table 3
Potential modulation of SP-D function
Altered patterns of oligomerization
Liberation of trimeric subunits secondary to proteolytic degradation
Self-aggregation
Modifications of the CRD
Proteolytic degradation
Oxidative modification
Local pH and calcium concentration
Competing ligands
LPS
Microorganisms
Host lectins with overlapping specificity
Mannose receptor
Other collectins (SP-A, mannose-binding lectin)
Non C-type lectins (such as ficolins)
Host lectins with overlapping specificity
It is difficult to predict the functions of SP-D within the air-
space. Other lectins with overlapping specificity are also
present. Although the levels of mannose-binding lectin are
probably low in the absence of increased vascular perme-
ability, SP-A and the macrophage mannose receptor could
conceivably interact with the same ligands in the distal
airways and alveoli. Such interactions could lead to antago-
nistic or cooperative effects. Furthermore, we have little
knowledge regarding the microanatomic distribution of
these molecules in specific circumstances in vivo.
Although most SP-A is probably associated with the insolu-
ble phase of the alveolar lining material, and the
macrophage mannose receptor is membrane-associated,
the distribution might be altered in the setting of lung injury.
In vivo models of SP-D deficiency
Models of SP-D deficiency show no detectable anatomical
or physiological abnormalities at birth. However, the animals
gradually develop a patchy, subpleural alveolar lipidosis with
associated type II cell hypertrophy, the accumulation of
enlarged and foamy macrophages, and an apparent expan-
sion of peribronchial lymphoid tissue [85•,86•]. Interestingly,
the mice eventually develop distal-acinar emphysema and
areas of subpleural fibrosis, which could reflect a continuing
inflammatory reaction associated with abnormal oxidant
metabolism and metalloproteinase activity [87•]. By con-
trast, SP-A-deficient mice (–/–) show essentially normal res-
piratory function and surfactant lipid metabolism [88,89] but
numerous apparent host defense abnormalities [90].
SP-D: in vivo models of microbial challenge
Challenge of normal mice
The capacity of SP-D to bind to specific strains of
influenza A in vitro is highly correlated with the capacity of
the virus to proliferate in mice in vivo [62]. Specifically,
strains with more oligosaccharide attachments on the HA
are preferentially neutralized by SP-D in vitro and show
decreased proliferation in mice. Because the administra-
tion of mannan together with the virus increased the repli-
cation of IAV in the lung, the involvement of a
mannose-type, C-type lectin was implicated.
SP-D-sensitive IAV strains also replicate to higher titers in
the lungs of diabetic mice than in nondiabetic controls
[84•]. Replication of the virus is positively correlated with
blood glucose level, and decreases in response to insulin
treatment. Significantly, blood glucose levels comparable
to those measured in the diabetic mice were sufficient to
inhibit the interaction of SP-D with these viral strains in
vitro. PR-8, a strain that does not interact with SP-D but
does interact with SP-A, replicated to the same extent in
diabetic and control mice.
SP-D levels increase in association with certain infections.
For example, SP-D levels, but not the levels of serum
mannose-binding lectin, increase markedly after IAV infec-
tion [62]. Impressive increases in SP-D have also been
observed in murine models of Pneumocystis carinii [91]
and P. aeruginosa infection [92].
Challenge of SP-D-deficient mice
SP-D-deficient mice have not yet been extensively charac-
terized with respect to host defense function. However,
they show decreased viral clearance and enhanced inflam-
mation after challenge with respiratory syncytial virus [93]
and IAV (AM Levine, personal communication). In addition,
they show increased inflammation, increased oxidant pro-
duction, and decreased macrophage phagocytosis in
response to intratracheally instilled group B streptococcus
and Haemophilus influenzae (AM Levine, personal com-
munication). Although the overexpression of wild-type SP-
D in type II pneumocytes with the SP-D-deficient mice can
prevent the lipidosis and inflammatory changes [94], the
ability of overexpressed wild-type SP-D or exogenous SP-
D to ameliorate these abnormalities has not yet been
described. The coexisting pulmonary abnormalities also
complicate the interpretation of challenge models. For
example, macrophage activation might enhance killing and
offset any decrease that results more directly from SP-D
deficiency. SP-D deficiency modifies the host response to
instilled LPS with decreased lung injury and inflammatory
cell recruitment [50].
Possible roles of SP-D in acquired immunity
Molecules that can bind to potential antigens and deliver
them to macrophages and other antigen-presenting cells
might contribute to the development of acquired immunity.
In this regard, a few published observations suggest possi-
ble roles in the development of humoral and/or cellular
immunity in response to microorganisms or complex organic
antigens. For example, SP-D can decrease interleukin-2-
dependent T-lymphocyte proliferation [95•]. Interestingly,
single-arm mutants were at least as potent as intact dode-
camers in mediating this effect. SP-D also binds to
oligosaccharides associated with dust mite allergen [96•],
and can inhibit the binding of specific IgE to these allergens,
possibly through direct, CRD-dependent binding to lympho-
cytes [96•]. Thus, alterations in the level of SP-D (or the
state of oligomerization) might influence the development of
immunological responses and contribute to the pathogene-
sis of asthma and other hypersensitivity disorders.
There are other potential interplays between humoral
immunity and collectins with regard to antimicrobial host
defense. For example, increased glycosylation of IAV coat
proteins, an adaptation that is believed to help the virus to
evade antibody-mediated neutralization, is associated with
increased reactivity with SP-D and other collectins [62].
Thus, the relative potential importance of antibody and col-
lectin-mediated host defenses might be influenced by
subtle variations in the structure of the microbial surface.
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SP-D gene expression
Developmental regulation
There is little recent information on the developmental reg-
ulation of SP-D expression. In general, SP-D increases
rapidly late in gestation [97–100]. The production of SP-D
increases during the culture of fetal lung explants, and
expression can be increased with glucocorticoids
[98,100,101]. The exposure of fetal rats to glucocorti-
coids in vivo leads to precocious expression with
increased numbers of SP-D-expressing cells and
increased cellular levels of SP-D message [98,101,102].
Altered expression with lung injury
Although SP-D is produced constitutively within the lung,
protein accumulation and gene expression are inducible
and increases in SP-D expression have been observed in a
number of disease states or models (Tables 4 and 5). In
general, the synthesis and secretion of SP-D increase in
association with lung injury and activation of the respiratory
epithelium [1]. For example, levels of SP-D mRNA and SP-
D accumulation are increased within 24–72 h after intratra-
cheal instillation of LPS [103•], and SP-D expression by
alveolar and bronchiolar epithelial cells increases after
exposure of rats to 95% O2 for 12 h [104]. Keratinocyte
growth factor (KGF) increases SP-D expression and
protein production in association with pneumocyte hyper-
plasia and after injury caused by bleomycin [105]. In addi-
tion, the levels of SP-D can increase markedly in response
to the overexpression of certain cytokines, such as inter-
leukin-4, or in response to microbial challenge [91,92].
Transcriptional regulation
Studies of the upstream regulatory region of the SP-D
gene have demonstrated increased promoter activity in
the presence of glucocorticoids, which is consistent with
the findings in vivo and in lung organ culture [106].
However, no functional glucocorticoid response elements
have been identified, and the effects of dexamethasone
seem to be secondary and involve the effects of other
transregulatory molecules.
The activity of the human SP-D promoter is dependent on
a conserved activator protein-1 (AP-1) element (–109)
that binds to members of the fos and jun families of tran-
scriptional factors [107]. In addition, the promoter con-
tains multiple functional binding sites for
CCAAT-enhancer-binding protein (C/EBP) transcription
factors. Mutagenesis experiments suggest that these are
required for basal and stimulated promoter activity, and
promoter activity is markedly increased in H441 cells after
co-transfection with C/EBPβ cDNA (YC He and E crouch,
unpublished data). The importance of the conserved AP-1
element and the presence of multiple binding sites for
C/EBP transcription factors is consistent with the
observed modulation of SP-D expression in the setting of
tissue injury.
SP-D promoter activity is not dependent on the binding of
thyroid transcription factor 1 (TTF-1) [107]. However, pro-
moter activity is dependent on two interacting forkhead
binding sites, upstream and downstream of the AP-1
element; these sites bind to hepatic nuclear factor-3α and
apparently other forkhead box proteins in H441 lung ade-
nocarcinoma nuclear extracts [107].
Genetic variation
Initial comparison of genomic and cDNA sequence sug-
gested the existence of genetic polymorphisms in the
SP-D coding sequence, including one in the N-terminal
propeptide domain (Thr11 compared with Met11 in the
mature protein) and three additional differences within the
collagen domain at positions 102, 160, and 186 [108].
The latter substitutions are conservative to the extent that
they are not expected to disrupt the collagen helix. Floros
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Table 4
Potential alterations in human disease
Disease Abnormality References
Cystic fibrosis Decreased accumulation or [111]
depletion
Acute interstitial Decreased accumulation or [112]
pneumonias (ARDS) depletion
Cigarette smoking Decreased levels in lavage [113]
Bronchopulmonary Decreased accumulation or [114,115]
dysplasia depletion
Asthma Altered activity [75]
Alveolar proteinosis. Increased accumulation [116,117]
Diabetes mellitus Decreased activity? [84•]
Table 5
Increased SP-D accumulation or expression in animal models
Injury or challenge Species Reference
Silicosis Rat [118]
Hyperoxia Rat [104]
Endotoxin (LPS) Rat [103]
Challenge with P. aeruginosa Mouse [92]
Challenge with IAV Mouse [62]
Challenge with Pneumocystis carinii SCID mouse [91]
Rat [119]
Overexpression of interleukin-4 Mouse [120]
SCID, severe combined immunodeficiency.
and co-workers have recently confirmed the existence of
polymorphisms at positions 11 and 160 of the mature
protein [109]. The potential biological significance, if any,
is not known. Interestingly, the 50 kDa variant of SP-D
showed O-linked glycosylation of Thr11 [32•], suggesting
that this polymorphism might be associated with altered
glycosylation. Interestingly, the 50 kDa variant was recov-
ered as trimeric subunits, raising the possibility that differ-
ences in the glycosylation of residue 11, which is
immediately N-terminal to Cys15, could influence multi-
merization and the capacity of SP-D to participate in bridg-
ing interactions.
Conclusion
There is increasing evidence that SP-D interacts specifi-
cally with a wide variety of respiratory pathogens, modu-
lates the leukocyte response to these organisms, and
participates in aspects of pulmonary immune and inflamma-
tory regulation (Table 6). SP-D can influence the activity of
phagocytes through CRD-dependent and CRD-indepen-
dent interactions. At least some of the effects of SP-D
result from aggregation with enhanced binding of the
agglutinated ligand to their natural ‘receptors’. Although the
lung is the major site of SP-D expression, it is likely that the
protein has more generalized roles in host defense and the
acute response to infection and tissue injury.
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